256 related articles for article (PubMed ID: 22134373)
21. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological interactions between adenosine A
Pinna A; Serra M; Marongiu J; Morelli M
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
[TBL] [Abstract][Full Text] [Related]
23. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
24. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
25. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
26. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.
Ferré S; Ciruela F; Canals M; Marcellino D; Burgueno J; Casadó V; Hillion J; Torvinen M; Fanelli F; Benedetti Pd Pd; Goldberg SR; Bouvier M; Fuxe K; Agnati LF; Lluis C; Franco R; Woods A
Parkinsonism Relat Disord; 2004 Jul; 10(5):265-71. PubMed ID: 15196504
[TBL] [Abstract][Full Text] [Related]
27. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
[TBL] [Abstract][Full Text] [Related]
28. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
30. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.
Armentero MT; Pinna A; Ferré S; Lanciego JL; Müller CE; Franco R
Pharmacol Ther; 2011 Dec; 132(3):280-99. PubMed ID: 21810444
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
[TBL] [Abstract][Full Text] [Related]
32. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
Volpini R; Dal Ben D; Lambertucci C; Marucci G; Mishra RC; Ramadori AT; Klotz KN; Trincavelli ML; Martini C; Cristalli G
ChemMedChem; 2009 Jun; 4(6):1010-9. PubMed ID: 19343763
[TBL] [Abstract][Full Text] [Related]
33. Development of Adenosine A
Zheng J; Zhang X; Zhen X
ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
[TBL] [Abstract][Full Text] [Related]
34. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
Antonelli T; Fuxe K; Agnati L; Mazzoni E; Tanganelli S; Tomasini MC; Ferraro L
J Neurol Sci; 2006 Oct; 248(1-2):16-22. PubMed ID: 16765381
[TBL] [Abstract][Full Text] [Related]
35. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Pinna A; Wardas J; Simola N; Morelli M
Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
[TBL] [Abstract][Full Text] [Related]
36. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Collins LE; Sager TN; Sams AG; Pennarola A; Port RG; Shahriari M; Salamone JD
Pharmacol Biochem Behav; 2012 Jan; 100(3):498-505. PubMed ID: 22037410
[TBL] [Abstract][Full Text] [Related]
37. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
38. Role of adenosine A
Pinna A; Serra M; Morelli M; Simola N
J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
[TBL] [Abstract][Full Text] [Related]
39. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF
J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483
[TBL] [Abstract][Full Text] [Related]
40. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF
J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
